Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Kura Oncology, Inc.NASDAQ: KURA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $8.42M rose 7.3% year over year, behind the +13.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 25.9% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.
Context
- Stock-based compensation amounted to 55.0% of revenue in FY2025, down 7.9 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +7.3% toward the trailing-twelve-month pace of +13.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 37.11M USD
- Year-over-year change
- +9.5%
- 4-year CAGR
- +12.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.11M | +9.5% |
| FY2024 | 2024-12-31 | 33.9M | +20.7% |
| FY2023 | 2023-12-31 | 28.08M | +6.7% |
| FY2022 | 2022-12-31 | 26.32M | +11.6% |
| FY2021 | 2021-12-31 | 23.58M | — |
Stock-Based Compensation vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's LTM Mar 2026 stock-based compensation of $37.68M is the 3rd largest of the 11 companies compared; the peer median is $15.42M.
- Its year-over-year change of +13.4% is the 8th highest of 11, against a peer median of +20.5%.
- Stock-based compensation amounts to 52.6% of revenue for KURA, versus a peer median of 12.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $49.18M | +10.5% | +43.7% | 22.6% | |
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
| LTM Mar 2026 | $37.68M | +13.4% | +12.1% | 52.6% | |
| LTM Mar 2026 | $29.43M | +17.2% | +38.3% | — | |
| LTM Mar 2026 | $25.38M | +66.4% | — | — | |
| LTM Jun 2025 | $17.99M | -47.3% | -20.6% | 3.0% | |
| LTM Mar 2026 | $12.84M | +21.4% | +0.9% | 4.3% | |
| LTM Mar 2026 | $9.66M | +26.4% | +15.9% | 19.5% | |
| LTM Mar 2026 | $5.99M | +19.7% | +10.2% | 1140.6% | |
| LTM Sep 2026 | $4.19M | +122.7% | +4.3% | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $3.82M | +1696.3% | — | — |
| Peer median (excluding KURA) | $15.42M | +20.5% | +10.3% | 12.6% | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | (7.46M) |
| Deferred Income Tax | 4.6M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.58M | 26.32M | 28.08M | 33.9M | 37.11M |
| Change in Working Capital | (3.22M) | (2.98M) | 7.82M | 286.17M | 184.44M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (6.74M) |
| Inventory | 0 | 0 | 0 | 0 | (413K) |
| Accounts Payables | (2.52M) | (802K) | 10.33M | 15.2M | 4.5M |
| Other Working Capital | (706K) | (2.18M) | (2.51M) | 270.97M | 187.1M |
| Other Non-Cash Items | 399K | 1.68M | (8.94M) | (12.62M) | 515K |
| Operating Cash Flow | (104.55M) | (110.06M) | (124.82M) | 134.32M | (64.06M) |
| Capital Expenditures | (1.15M) | (626K) | (168K) | (472K) | (6.64M) |
| Acquisitions (Net) | 125.69K | (33.25K) | 0 | 0 | 0 |
| Purchases of Investments | (445.66M) | (270.66M) | (409.82M) | (659.05M) | (761.59M) |
| Sales of Investments | 319.97M | 303.91M | 425.55M | 557.93M | 755.13M |
| Other Investing Activities | (125.69K) | 33.25K | 0 | 0 | 0 |
| Investing Cash Flow | (126.84M) | 32.63M | 15.56M | (101.59M) | (13.1M) |
| Debt Repayment | (7.25M) | 10M | 0 | 0 | 0 |
| Common Stock Issued | 4.43M | 24.72M | 93.58M | 145.81M | 1.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (611K) | 3.84M | 1.21M | 8.6M | 0 |
| Financing Cash Flow | (3.44M) | 38.57M | 94.78M | 154.42M | 1.79M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (234.82M) | (38.87M) | (14.48M) | 187.14M | (75.36M) |
| Free Cash Flow | (105.7M) | (110.69M) | (124.99M) | 133.85M | (70.7M) |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.